Who is the CEO of Kringle Pharma, Inc.?

The CEO of Kringle Pharma, Inc. is Kiichi Adachi.

What industry does Kringle Pharma, Inc. belong to?

Kringle Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector.

Where is Kringle Pharma, Inc. headquartered?

Kringle Pharma, Inc. is headquartered at 207 Saito Bio Incubator, Ibaraki, 567-0085, JP.

What is the IPO date of Kringle Pharma, Inc.?

Kringle Pharma, Inc. went public on December 28, 2020.

How many employees does Kringle Pharma, Inc. have?

Kringle Pharma, Inc. has approximately 15 full-time employees.

Kringle Pharma, Inc.

4884.T•JPX

Healthcare

Biotechnology

¥505.00

¥5.00(1.00%)

Kringle Pharma, Inc. (4884.T) Company Profile & Overview

Explore Kringle Pharma, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Kringle Pharma, Inc. (4884.T) Company Profile & Overview

Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.

SectorHealthcare

IndustryBiotechnology

CEOKiichi Adachi

Contact Information

https://www.kringle-pharma.com

81 7 2641 8739

207 Saito Bio Incubator, Ibaraki, 567-0085

Company Facts

15 Employees

IPO DateDec 28, 2020

CountryJP

Actively Trading

Frequently Asked Questions

;